Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IronEx: Sequential Iron Therapy and Exercise in HFrEF
NCT03803111Withdrawn
- Sponsor
- Herzzentrum Bremen
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ferric carboxymaltose in heart failure with reduced ejection fraction (HFrEF) and iron deficiency anemia (IDA), sponsored by Herzzentrum Bremen. Primary endpoint: Peak Oxygen Uptake at 4 months. Planned start Jan 2021; status: withdrawn.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with reduced ejection fraction (HFrEF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03803111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03803111.